contents

america
 

2008 iBIO Industry Expo & Marketplace

The Illinois Biotechnology Industry Organization is honored to announce that Dr. B. Joseph White, President, University of Illinois; Yoshihiko Hatanaka, President and CEO, Astellas US, LLC; and Dr. Paul A. Willems, Technology Vice President, Energy Biosciences, BP Group will be they keynote speakers at the 2008 iBIO Industry Expo & Marketplace. The daylong conference is February 20, 2008 at the Hyatt Regency Hotel in downtown Chicago. "The iBIO IndEx is recognized as the premier event for the life sciences industry in the Midwest, " said iBIO President and CEO David Miller.

Dr. White has served as President of the University of Illinois since January 2005. He has written, taught and lectured extensively on leadership, management and organizational matters. Prior to joining the University of Illinois, Dr. White spent nearly three decades affiliated with the University of Michigan at Ann Arbor, where he received his doctorate in business administration in 1975.

Mr. Yoshihiko Hatanaka leads Astellas US LLC, a subsidiary of Astellas Pharma Inc., based in Tokyo, Japan. Mr. Hatanaka's career spans twenty-six years with Astellas (formerly Fujisawa) in various marketing and corporate development positions. Mr. Hatanaka's experience in marketing began when he joined the company in 1980 as a Marketing Analyst, Pharmaceutical Division, in Osaka, Japan, and then spent several years as a Medical Sales Representative before advancing to Associate Manager, Marketing Planning in the Tokyo office. He was assigned to the U.S. in 1992 as Director, Marketing Planning, Immunology. While in the U.S., Mr. Hatanaka planned the launch strategy in the United States and Canada for Prograf, Astellas' transplant immunosuppressant, and coordinated the Prograf global launch preparation activities.

As Technology Vice President for Energy Biosciences in BP, Dr. Paul Willems is responsible for integrating biotechnology into BP's business activity. His duties include leading the development and execution of an integrated technology strategy which incorporates all of BP's bio-related activity and which is fully integrated with BP's company-wide business strategies. Dr. Willems is also the Associate Director for the Energy Biosciences Institute, a 10-year research collaboration between the University of California at Berkeley, the Lawrence Berkeley National Lab, the University of Illinois in Urbana-Champaign and BP. In this capacity he is responsible for providing strategic input into the Institute's overall mission and research programs and for integrating the research results and capabilities of the Institute into BP's business activities.

A chemical engineer, Dr. Willems has held a variety of technical, manufacturing and commercial leadership roles throughout his 20-year career. He previously served as Business Technology Manager for BP's global PTA (purified terephthalic acid, a polyester raw material) business, and as Technology Vice President for acetyls and aromatics. In this capacity, he guided the development of BP's next generation PTA technology. Dr. Willems has deep experience in the development, scale up and commercialization of manufacturing technologies for commodity chemicals. Dr. Willems earned a Ph.D. in Chemical Engineering from the University of Ghent in Belgium in 1986.



write your comments about the article :: 2008 Exhibition News :: home page